Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas
Article
Villalona, MA, Bekaii-Saab, T, Burak, W et al. (2005). Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas
. JOURNAL OF CLINICAL ONCOLOGY, 23(16_suppl), 4027-4027. 10.1200/jco.2005.23.16_suppl.4027
Villalona, MA, Bekaii-Saab, T, Burak, W et al. (2005). Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas
. JOURNAL OF CLINICAL ONCOLOGY, 23(16_suppl), 4027-4027. 10.1200/jco.2005.23.16_suppl.4027